A
Adina Soaita
Researcher at Boehringer Ingelheim
Publications - 4
Citations - 468
Adina Soaita is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Placebo & Maintenance therapy. The author has an hindex of 3, co-authored 4 publications receiving 341 citations.
Papers
More filters
Journal ArticleDOI
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan,William J. Sandborn,Geert R. D'Haens,Julián Panés,Arthur Kaser,Marc Ferrante,Edouard Louis,Denis Franchimont,Olivier Dewit,Ursula Seidler,Kyung-Jo Kim,Markus F. Neurath,Stefan Schreiber,Paul Scholl,Chandrasena Pamulapati,Bojan Lalovic,Sudha Visvanathan,Steven J. Padula,Ivona Herichova,Adina Soaita,David B. Hall,Wulf O. Böcher +21 more
TL;DR: In this short-term study, risankizumab was more effective than placebo for inducing clinical remission in patients with active Crohn's disease and selective blockade of interleukin-23 via inhibition of p19 might be a viable therapeutic approach in Crohn’s disease.
Journal ArticleDOI
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Brian G. Feagan,Julián Panés,Marc Ferrante,Arthur Kaser,Geert R. D'Haens,William J. Sandborn,Edouard Louis,Markus F. Neurath,Denis Franchimont,Olivier Dewit,Ursula Seidler,Kyung-Jo Kim,Christian P. Selinger,Steven J. Padula,Ivona Herichova,Anne M. Robinson,Kori Wallace,Jun Zhao,Mukul Minocha,Ahmed A. Othman,Adina Soaita,Sudha Visvanathan,David B. Hall,Wulf O. Böcher +23 more
TL;DR: Risankizumab was well tolerated with no new safety signals noted and clinical remission was maintained in 44 (71%) patients; 50 (81%) patients had a clinical response, 22 (35%) patients were in endoscopic remission, and 34 (55%) patientshad an endoscopic response.
Journal ArticleDOI
812a Efficacy and Safety of Induction Therapy With the Selective IL-23 Inhibitor BI 655066, in Patients With Moderate-to-Severe Crohn's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Brian G. Feagan,William J. Sandborn,Julián Panés,Marc Ferrante,Edouard Louis,Geert R. D'Haens,Denis Franchimont,Arthur Kaser,Olivier Dewit,Ursula Seidler,Kyung-Jo Kim,Markus F. Neurath,Paul Scholl,Sudha Visvanathan,Steven J. Padula,Ivona Herichova,Adina Soaita,David B. Hall,Wulf O. Böcher +18 more
Journal ArticleDOI
Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderateto-Severe Crohn's Disease
Brian G. Feagan,Julián Panés,Marc Ferrante,Arthur Kaser,Geert R. D'Haens,William J. Sandborn,Edouard Louis,Markus F. Neurath,Denis Franchimont,Olivier Dewit,Ursula Seidler,Kyung-Jo Kim,Christian P. Selinger,Steven J. Padula,Ivona Herichova,Anne M. Robinson,Kori Wallace,Jun Zhao,Adina Soaita,Sudha Visvanathan,David B. Hall,Wulf O. Böcher +21 more